RECENT POSTS
Tuesday, January 8, 2019
A Look at Climate Change Disclosures

Wednesday, January 2, 2019
Quants: Point-in-Time Data for Backtesting

Friday, December 28, 2018
Now Showing: Controls & Procedures

Thursday, December 27, 2018
A Reminder on Non-GAAP Reporting Rules

Monday, December 17, 2018
Researching PG&E’s Wildfire Risk

Wednesday, December 12, 2018
Tracking Brexit Disclosures

Thursday, December 6, 2018
Campbell Soup: Looking Behind the Label

Sunday, December 2, 2018
SEC Comment Letters: The Amazon Example

Wednesday, November 28, 2018
Measuring Big Pharma’s Chemical Dependency

Monday, November 26, 2018
Analysts, Can You Relate? A True Story

Monday, November 19, 2018
Digging Up Historical Trend Data: Quest Example

Sunday, November 11, 2018
Cost of Revenue, SG&A: Q3 Update

Monday, November 5, 2018
Lease Accounting: FedEx vs. UPS

Saturday, November 3, 2018
New Email Alerting Powers

Wednesday, October 31, 2018
PTC and Two Tales of Revenue

Tuesday, October 30, 2018
10-K/Q Section Text Change Detection

Sunday, October 28, 2018
Finding Purchase Price Allocation

Sunday, October 21, 2018
Charting Netflix Growth in Three Ways

Wednesday, October 17, 2018
Interesting Data on Interest Income

Thursday, October 11, 2018
The Decline of Sears in Three Charts

Archive  |  Search:

Well, congress is at it again…that’s the bad news. The great news is that even since the last house vote on the foolishly titled ‘small company disclosure simplification act’ in January, we have a lot more to talk about in terms of the value of XBRL.

We’ve just completed another 10-K season for XBRL filings, which marks the 4th since XBRL was phased in for all size companies. This means we finally have 5+ years of history in XBRL for all firms. This is definitely a milestone that users will take notice of.

And at Calcbench we’re busy working on a very interesting project using AI to link numeric footnote data back to the HTML document. In other words, a simulated version of inline XBRL. More on that soon.

In the meantime, here are the FIVE BEST REASONS TO OPPOSE HR 1965:

1. XBRL is working
• XBRL provides access to corporate financial data significantly faster, in more detail, and at a lower cost than ever before. As a result, despite early hurdles, adoption has been steadily growing over the past 5 years.
• Calcbench users include Wall Street analysts, academics at major research universities, auditing firms, CFO offices, regulatory agencies, journalists and more.
• In additional to Calcbench, several large data providers now use XBRL as part of their retrieval process, and as a result, thousands of institutional investors now rely on this data.

2. The cost of XBRL is miniscule compared to the other costs of being a public company
• Smaller firms pay in the range of $10,000 a year according to this AICPA study.
• Meanwhile, the group of companies that would be exempt under this bill paid over $1 billion in legal and investment banking fees in 2013 just to raise capital from investors.

3. There is no such thing as a publicly listed ‘small, emerging growth’ company
• The U.S. has an extremely vibrant venture capital and private equity infrastructure. Small emerging growth companies have numerous options and amazing access to capital from sophisticated professional investors.
• HOWEVER once a company goes public and sells shares to retail investors, it has entered the major leagues. Along with this privilege comes responsibility. If you are too small to report your data, you are too small to be on the NASDAQ.

4. Revenue is a lousy indicator of a company’s size.
• It is no coincidence that the BIO association and the authors of this bill chose revenue as the threshold. After all biotech companies are often characterized by having low revenue for years until they release a hit drug.
• There are as many as 800 firms with assets over $1 BILLION that would be exempted by this bill.
• In fact all exempted companies totaled over $1.89 trillion in assets in 2013. Does that sound like small, emerging growth?

5. It’s 2015! Let’s not go back to the stone ages
• XBRL is in large part about maintaining the US’s status as the worldwide leader in capital markets. Talking about returning to a paper system in the year 2015 is just embarrassing.


FREE Calcbench Premium
Two Week Trial

Research Financial & Accounting Data Like Never Before. More features and try our Excel add-in. Sign up now to try the Premium Suite.